Hospital-Level Variation in COVID-19 Treatment Among Hospitalized Adults in the United States
During the first 2 years of the pandemic, there was relatively consistent use of dexamethasone and remdesivir across the hospitals examined. Consistent adoption and implementation of treatment guidelines across the hospitals examined may have led to a decrease in variation in drug usage over time.
Authors
- Hemalkumar B. Mehta (ORCID: https://orcid.org/0000-0001-9134-6370)
- Kenneth Sands (ORCID: https://orcid.org/0000-0002-1379-9793)
- G. Caleb Alexander (ORCID: https://orcid.org/0000-0002-5622-2986)
- Brian T. Garibaldi (ORCID: https://orcid.org/0000-0001-8632-5567)
- Joshua Betz (ORCID: https://orcid.org/0000-0003-4488-9799)
- Arielle M. Fisher (ORCID: https://orcid.org/0000-0002-8635-9705)
- Shanna A. Arnold Egloff (ORCID: https://orcid.org/0000-0002-6472-939X)
- Yanxun Xu
- Kathleen M. Andersen (ORCID: https://orcid.org/0000-0003-2670-800X)
- Huijun An (ORCID: https://orcid.org/0000-0003-2907-3185)
- Kunbo Wang (ORCID: https://orcid.org/0000-0002-7850-5928)
- Matthew L. Robinson (ORCID: https://orcid.org/0000-0003-0376-8560)
- Albert W. Wu
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- HCA Healthcare (US)
- Sarah Cannon (US)
Publication Details
- Journal
- Medical Care
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1097/mlr.0000000000002086
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- John Templeton Foundation
- Pfizer
- Gilead Sciences
- HCA Healthcare
- Genentech
- Janssen Research and Development